| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| T2023 |
Targeted case management; per month |
12,210 |
10,701 |
$4.04M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
55,431 |
23,052 |
$2.98M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
26,659 |
16,604 |
$1.28M |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
6,141 |
4,273 |
$985K |
| H0038 |
Self-help/peer services, per 15 minutes |
43,803 |
17,962 |
$757K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
6,259 |
5,373 |
$374K |
| 90853 |
Group psychotherapy (other than of a multiple-family group) |
18,619 |
11,086 |
$311K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
10,134 |
5,832 |
$265K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
822 |
607 |
$181K |
| H0015 |
Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education |
1,293 |
236 |
$167K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
10,664 |
7,478 |
$162K |
| 90832 |
Psychotherapy, 30 minutes with patient |
3,216 |
2,397 |
$135K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
987 |
598 |
$114K |
| 90791 |
Psychiatric diagnostic evaluation |
1,183 |
968 |
$82K |
| T1007 |
Alcohol and/or substance abuse services, treatment plan development and/or modification |
964 |
914 |
$70K |
| 81025 |
|
4,656 |
4,305 |
$36K |
| H0049 |
Alcohol and/or drug screening |
2,153 |
1,753 |
$34K |
| H2015 |
Comprehensive community support services, per 15 minutes |
1,558 |
863 |
$33K |
| 90837 |
Psychotherapy, 53 minutes with patient |
361 |
299 |
$26K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
304 |
262 |
$18K |
| 99205 |
Prolong outpt/office vis |
228 |
196 |
$17K |
| 80061 |
Lipid panel |
1,244 |
1,167 |
$15K |
| 90833 |
Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) |
153 |
131 |
$8K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
136 |
123 |
$6K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
57 |
50 |
$6K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
160 |
150 |
$6K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
712 |
656 |
$6K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
99 |
88 |
$5K |
| G0438 |
Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit |
61 |
57 |
$4K |
| 80306 |
|
528 |
450 |
$4K |
| 36415 |
Collection of venous blood by venipuncture |
815 |
695 |
$4K |
| H0032 |
Mental health service plan development by non-physician |
40 |
39 |
$3K |
| 99385 |
|
44 |
41 |
$3K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
30 |
28 |
$2K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
26 |
25 |
$2K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
162 |
151 |
$1K |
| 99215 |
Prolong outpt/office vis |
15 |
12 |
$988.82 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
66 |
52 |
$679.24 |
| 90674 |
|
36 |
30 |
$559.54 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
37 |
18 |
$450.16 |
| 99441 |
|
21 |
16 |
$394.23 |
| 90686 |
|
24 |
20 |
$368.79 |
| H0025 |
Behavioral health prevention education service (delivery of services with target population to affect knowledge, attitude and/or behavior) |
18 |
13 |
$289.41 |
| 91200 |
|
21 |
14 |
$251.06 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
21 |
18 |
$228.11 |
| 86318 |
|
18 |
14 |
$200.80 |